X4 Pharmaceuticals (XFOR)
X4 Pharmaceuticals on one page: short interest, daily short volume, fails to deliver, large holders, 13F holders, earnings dates and insider trades. Listed on Nasdaq, classified by the SEC as biological products, (no diagnostic substances).
7.5M
Short interest
settlement 2026-10-15
12.5
Days to cover
+6.5 days vs prior
46.9%
Short share of volume
2026-11-02
250
Fails to deliver
settlement 2026-10-05
Wed 4 Nov
Next earnings
estimated date
-$342K
Insider flow, 90 days
1 buys, 3 sells
As of 2026-11-02.
Short interest
FINRA, twice a month. The newest 48 settlements in the table, 48 in the chart. JSONAs of 15 October 2026, short interest in XFOR is 7,490,770 shares, down 745,705 shares over the last month. Over the last 48 readings it ranged from 290,703 shares (30 April 2025) to 16,606,425 shares (31 January 2025). At the reported average volume of 599K shares a day that is 12.5 days to cover.
Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/xfor" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-10-15 | 7,490,770 | -1.3% | 599,106 | 12.50 |
| 2026-09-30 | 7,590,000 | -7.8% | 1,256,869 | 6.04 |
| 2026-09-15 | 8,236,475 | +14.6% | 1,164,513 | 7.07 |
| 2026-08-31 | 7,190,058 | +0.3% | 560,027 | 12.84 |
| 2026-08-14 | 7,164,662 | -1.9% | 803,567 | 8.92 |
| 2026-07-31 | 7,300,120 | +12.3% | 572,776 | 12.75 |
| 2026-07-15 | 6,501,966 | +18.1% | 663,901 | 9.79 |
| 2026-06-30 | 5,507,057 | +31.7% | 1,586,041 | 3.47 |
| 2026-06-15 | 4,180,487 | +24.0% | 421,393 | 9.92 |
| 2026-05-29 | 3,371,418 | +15.3% | 363,115 | 9.28 |
| 2026-05-15 | 2,923,580 | -6.2% | 344,226 | 8.49 |
| 2026-04-30 | 3,117,372 | -0.9% | 373,452 | 8.35 |
| 2026-04-15 | 3,144,815 | +0.7% | 414,981 | 7.58 |
| 2026-03-31 | 3,123,686 | -10.7% | 436,290 | 7.16 |
| 2026-03-13 | 3,498,089 | +1.2% | 619,124 | 5.65 |
| 2026-02-27 | 3,456,380 | +2.3% | 561,715 | 6.15 |
| 2026-02-13 | 3,379,356 | +8.3% | 518,827 | 6.51 |
| 2026-01-30 | 3,121,800 | +0.9% | 248,022 | 12.59 |
| 2026-01-15 | 3,094,769 | +3.1% | 422,814 | 7.32 |
| 2025-12-31 | 3,001,615 | -4.9% | 1,027,887 | 2.92 |
| 2025-12-15 | 3,155,605 | +27.1% | 747,734 | 4.22 |
| 2025-11-28 | 2,482,029 | +27.8% | 487,977 | 5.09 |
| 2025-11-14 | 1,942,100 | +30.1% | 559,677 | 3.47 |
| 2025-10-31 | 1,492,168 | -16.4% | 2,427,246 | 1.00 |
| 2025-10-15 | 1,785,248 | -12.8% | 390,222 | 4.57 |
| 2025-09-30 | 2,047,594 | +8.2% | 433,130 | 4.73 |
| 2025-09-15 | 1,892,311 | +21.7% | 618,562 | 3.06 |
| 2025-08-29 | 1,554,621 | -37.0% | 2,549,093 | 1.00 |
| 2025-08-15 | 2,466,929 | +141.5% | 16,995,141 | 1.00 |
| 2025-07-31 | 1,021,497 | +161.7% | 2,717,708 | 1.00 |
| 2025-07-15 | 390,377 | +3.6% | 527,856 | 1.00 |
| 2025-06-30 | 376,874 | -22.3% | 440,414 | 1.00 |
| 2025-06-13 | 484,831 | +22.2% | 439,308 | 1.10 |
| 2025-05-30 | 396,893 | +27.1% | 185,380 | 2.14 |
| 2025-05-15 | 312,303 | +7.4% | 179,764 | 1.74 |
| 2025-04-30 | 290,703 | -96.7% | 142,275 | 2.04 |
| 2025-04-15 | 8,798,612 | +9.0% | 1,858,663 | 4.73 |
| 2025-03-31 | 8,075,118 | -6.5% | 1,847,051 | 4.37 |
| 2025-03-14 | 8,641,381 | -8.8% | 1,509,932 | 5.72 |
| 2025-02-28 | 9,480,584 | -14.3% | 1,316,431 | 7.20 |
| 2025-02-14 | 11,061,185 | -33.4% | 2,416,416 | 4.58 |
| 2025-01-31 | 16,606,425 | +22.6% | 10,403,264 | 1.60 |
| 2025-01-15 | 13,550,472 | +1.4% | 3,136,688 | 4.32 |
| 2024-12-31 | 13,360,196 | +1.2% | 2,811,619 | 4.75 |
| 2024-12-13 | 13,204,412 | +5.6% | 4,669,519 | 2.83 |
| 2024-11-29 | 12,501,447 | -3.4% | 2,224,217 | 5.62 |
| 2024-11-15 | 12,938,054 | +13.3% | 7,759,538 | 1.67 |
| 2024-10-31 | 11,424,210 | -9.8% | 1,322,431 | 8.64 |
Daily short volume
FINRA Reg SHO, the last 30 sessions. JSONAs of 2 November 2026, the short share of XFOR volume is 46.9%, down 28.1 points over the last five sessions. Over the last 30 readings it ranged from 10.0% (30 September 2026) to 78.8% (21 October 2026). The latest reading is 4.3 points below the 30-session average of 51.3%, on 210K shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-11-02 | 98K | 210K | 46.9% | 0 |
| 2026-10-30 | 115K | 336K | 34.4% | 0 |
| 2026-10-29 | 204K | 354K | 57.6% | 5,168 |
| 2026-10-28 | 117K | 218K | 53.6% | 0 |
| 2026-10-27 | 347K | 985K | 35.3% | 2,362 |
| 2026-10-26 | 195K | 260K | 75.0% | 0 |
| 2026-10-23 | 132K | 174K | 76.1% | 0 |
| 2026-10-22 | 160K | 213K | 75.0% | 2,211 |
| 2026-10-21 | 121K | 153K | 78.8% | 0 |
| 2026-10-20 | 134K | 201K | 66.8% | 2,000 |
| 2026-10-19 | 155K | 238K | 65.4% | 50 |
| 2026-10-16 | 226K | 411K | 54.9% | 300 |
| 2026-10-15 | 124K | 265K | 46.7% | 0 |
| 2026-10-14 | 143K | 289K | 49.5% | 1,700 |
| 2026-10-13 | 100K | 203K | 49.3% | 0 |
| 2026-10-12 | 96K | 199K | 48.0% | 0 |
| 2026-10-09 | 136K | 251K | 54.4% | 2,604 |
| 2026-10-08 | 82K | 175K | 46.8% | 0 |
| 2026-10-07 | 103K | 150K | 68.6% | 79 |
| 2026-10-06 | 124K | 179K | 69.2% | 300 |
| 2026-10-05 | 139K | 181K | 76.6% | 111 |
| 2026-10-02 | 173K | 360K | 47.9% | 0 |
| 2026-10-01 | 92K | 157K | 58.7% | 0 |
| 2026-09-30 | 134K | 1.3M | 10.0% | 0 |
| 2026-09-29 | 159K | 1.2M | 13.2% | 2,816 |
| 2026-09-28 | 131K | 349K | 37.5% | 2,713 |
| 2026-09-25 | 169K | 1.2M | 14.2% | 0 |
| 2026-09-24 | 236K | 494K | 47.6% | 9,080 |
| 2026-09-23 | 747K | 1.5M | 50.0% | 3,533 |
| 2026-09-22 | 168K | 559K | 30.1% | 0 |
Fails to deliver
SEC, the last 30 settlement dates with a fail. JSONAs of 5 October 2026, the fails-to-deliver balance in XFOR is 250 shares, down 2,519 shares over the last settlement date. Over the last 30 readings it ranged from 3 shares (31 July 2026) to 298,075 shares (16 September 2026). The latest reading sits at the bottom of that range.
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-10-05 | 250 | $2.83 | $708 |
| 2026-10-01 | 2,769 | $2.90 | $8K |
| 2026-09-30 | 1,021 | $2.90 | $3K |
| 2026-09-18 | 1,663 | $3.50 | $6K |
| 2026-09-16 | 298,075 | $3.62 | $1.1M |
| 2026-09-15 | 294 | $3.62 | $1K |
| 2026-09-11 | 11,061 | $3.40 | $38K |
| 2026-09-10 | 16,528 | $3.60 | $60K |
| 2026-09-09 | 10 | $3.51 | $35 |
| 2026-09-08 | 21 | $4.04 | $85 |
| 2026-08-20 | 201 | $4.16 | $836 |
| 2026-08-14 | 3,414 | $4.29 | $15K |
| 2026-08-06 | 1,797 | $4.15 | $7K |
| 2026-07-31 | 3 | $4.00 | $12 |
| 2026-07-13 | 175 | $4.41 | $772 |
| 2026-07-08 | 1,513 | $3.94 | $6K |
| 2026-06-30 | 196,089 | $4.23 | $829K |
| 2026-06-29 | 204,100 | $4.02 | $820K |
| 2026-06-16 | 3,072 | $4.08 | $13K |
| 2026-05-13 | 1,276 | $4.34 | $6K |
| 2026-05-08 | 1,530 | $4.29 | $7K |
| 2026-05-07 | 148 | $4.38 | $648 |
| 2026-05-04 | 1,777 | $4.19 | $7K |
| 2026-04-30 | 5,379 | $4.10 | $22K |
| 2026-04-28 | 441 | $4.21 | $2K |
| 2026-04-24 | 1,316 | $4.28 | $6K |
| 2026-04-22 | 2,006 | $4.17 | $8K |
| 2026-04-17 | 1,925 | $4.14 | $8K |
| 2026-04-15 | 828 | $4.20 | $3K |
| 2026-04-13 | 5,262 | $4.10 | $22K |
Insider trades
SEC Form 4, newest first. JSONOver the last 90 days XFOR insiders reported 1 open-market buy ($12K) against 3 sells ($354K), so the dollar flow leans toward selling. Latest filing: Craig Adam R (Executive Chairman) on 2026-10-16.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-10-16 | Craig Adam R | Executive Chairman | Buy | 5K | $2.58 | $12K | 333K |
| 2026-10-01 | KIRSKE DAVID | Chief Financial Officer | Sell | 12K | $2.86 | $34K | 156K |
| 2026-08-12 | Volpone John | President | Sell | 25K | $4.44 | $109K | 265K |
| 2026-08-12 | Craig Adam R | Executive Chairman | Sell | 47K | $4.44 | $211K | 329K |
| 2026-06-30 | KIRSKE DAVID | Chief Financial Officer | Sell | 9K | $4.26 | $36K | 168K |
| 2026-05-12 | KIRSKE DAVID | Chief Financial Officer | Sell | 17K | $4.29 | $73K | 176K |
| 2025-10-23 | Craig Adam R | Executive Chairman | Buy | 86K | $2.90 | $250K | 376K |
| 2025-08-14 | Volpone John | President | Grant | 290K | $0.00 | $0 | 290K |
| 2025-08-14 | KIRSKE DAVID | Chief Financial Officer | Grant | 193K | $0.00 | $0 | 193K |
| 2025-08-14 | Craig Adam R | Executive Chairman | Grant | 290K | $0.00 | $0 | 290K |
| 2025-06-09 | WYZGA MICHAEL S | Director | Grant | 2K | $0.00 | $0 | 6K |
| 2025-06-09 | MCGIRR DAVID W J | Director | Grant | 2K | $0.00 | $0 | 5K |
| 2025-06-09 | Woods Keith | Director | Grant | 2K | $0.00 | $0 | 6K |
| 2025-06-09 | Bridger Gary | Director | Grant | 2K | $0.00 | $0 | 5K |
| 2025-06-09 | de Craecker Francoise | Director | Grant | 2K | $0.00 | $0 | 5K |
| 2025-06-09 | Stewart Murray | Director | Grant | 2K | $0.00 | $0 | 8K |
| 2025-05-20 | Thoren Natasha Fay | Chief Legal Officer | Grant | 3K | $0.00 | $0 | 9K |
| 2025-05-16 | Baldry Mark | Chief Commercial Officer | Buy | 1K | $2.48 | $3K | 25K |
| 2025-05-16 | Baldry Mark | Chief Commercial Officer | Grant | 1K | $2.48 | $3K | 25K |
| 2025-02-12 | DiBiase Mary | Chief Operating Officer | Grant | 650K | $0.00 | $0 | 1.1M |
| 2025-02-12 | Baldry Mark | Chief Commercial Officer | Grant | 600K | $0.00 | $0 | 729K |
| 2025-02-12 | Ragan Paula | President and CEO | Grant | 2.3M | $0.00 | $0 | 3.3M |
| 2025-02-12 | Mostafa Adam S. | Chief Financial Officer | Grant | 850K | $0.00 | $0 | 850K |
| 2025-02-12 | Arbet-Engels Christophe | Chief Medical Officer | Grant | 850K | $0.00 | $0 | 864K |
| 2025-01-24 | Arbet-Engels Christophe | Chief Medical Officer | Sell | 12K | $0.45 | $5K | 14K |
| 2025-01-24 | DiBiase Mary | Chief Operating Officer | Sell | 22K | $0.45 | $10K | 491K |
| 2025-01-24 | Baldry Mark | Chief Commercial Officer | Sell | 29K | $0.45 | $13K | 94K |
| 2025-01-24 | Mostafa Adam S. | Chief Financial Officer | Sell | 75K | $0.45 | $34K | 0 |
| 2025-01-24 | Ragan Paula | President and CEO | Sell | 76K | $0.45 | $34K | 1.1M |
| 2025-01-23 | Arbet-Engels Christophe | Chief Medical Officer | Grant | 26K | $0.00 | $0 | 26K |
| 2025-01-23 | DiBiase Mary | Chief Operating Officer | Grant | 61K | $0.00 | $0 | 513K |
| 2025-01-23 | Baldry Mark | Chief Commercial Officer | Grant | 75K | $0.00 | $0 | 123K |
| 2025-01-23 | Mostafa Adam S. | Chief Financial Officer | Grant | 75K | $0.00 | $0 | 75K |
| 2025-01-23 | Ragan Paula | President and CEO | Grant | 170K | $0.00 | $0 | 1.2M |
| 2024-11-15 | Baldry Mark | Chief Commercial Officer | Buy | 13K | $0.34 | $5K | 129K |
| 2024-11-15 | Ragan Paula | President and CEO | Sell | 32K | $0.39 | $12K | 994K |
| 2024-10-15 | Ragan Paula | President and CEO | Sell | 32K | $0.56 | $18K | 1.0M |
| 2024-10-07 | Taveras Arthur | Chief Scientific Officer | Sell | 77K | $0.56 | $43K | 388K |
| 2024-10-07 | DiBiase Mary | Chief Operating Officer | Sell | 68K | $0.57 | $39K | 452K |
| 2024-10-07 | Ragan Paula | President and CEO | Sell | 239K | $0.55 | $132K | 1.1M |
| 2024-10-07 | Baldry Mark | Chief Commercial Officer | Sell | 11K | $0.58 | $6K | 49K |
| 2024-10-07 | Mostafa Adam S. | Chief Financial Officer | Sell | 231K | $0.55 | $127K | 0 |
| 2024-10-04 | Taveras Arthur | Chief Scientific Officer | Grant | 231K | $0.00 | $0 | 465K |
| 2024-10-04 | DiBiase Mary | Chief Operating Officer | Grant | 231K | $0.00 | $0 | 520K |
| 2024-10-04 | Ragan Paula | President and CEO | Grant | 532K | $0.00 | $0 | 1.3M |
| 2024-10-04 | Baldry Mark | Chief Commercial Officer | Grant | 35K | $0.00 | $0 | 60K |
| 2024-10-04 | Mostafa Adam S. | Chief Financial Officer | Grant | 231K | $0.00 | $0 | 231K |
| 2024-09-09 | DiBiase Mary | Chief Operating Officer | Sell | 3K | $0.66 | $2K | 289K |
| 2024-06-10 | WYZGA MICHAEL S | Director | Grant | 45K | $0.00 | $0 | 122K |
| 2024-06-10 | Lawton Alison Frances | Director | Grant | 45K | $0.00 | $0 | 97K |
| 2024-06-10 | Woods Keith | Director | Grant | 45K | $0.00 | $0 | 135K |
| 2024-06-10 | Bridger Gary | Director | Grant | 45K | $0.00 | $0 | 97K |
| 2024-06-10 | Stewart Murray | Director | Grant | 45K | $0.00 | $0 | 192K |
| 2024-06-10 | MCGIRR DAVID W J | Director | Grant | 45K | $0.00 | $0 | 97K |
| 2024-06-10 | Aliski William | Director | Grant | 45K | $0.00 | $0 | 97K |
| 2024-06-10 | de Craecker Francoise | Director | Grant | 45K | $0.00 | $0 | 97K |
| 2024-05-17 | Baldry Mark | Chief Commercial Officer | Buy | 22K | $0.68 | $15K | 116K |
| 2024-03-11 | DiBiase Mary | Chief Operating Officer | Sell | 15K | $0.88 | $14K | 292K |
| 2024-03-11 | Mostafa Adam S. | Chief Financial Officer | Sell | 53K | $0.88 | $46K | 0 |
| 2024-03-11 | Ragan Paula | President and CEO | Sell | 50K | $0.88 | $44K | 765K |
| 2024-03-11 | Taveras Arthur | Chief Scientific Officer | Sell | 14K | $0.88 | $13K | 234K |
| 2024-02-12 | Mostafa Adam S. | Chief Financial Officer | Sell | 28K | $1.01 | $28K | 53K |
| 2024-02-12 | Ragan Paula | President and CEO | Sell | 22K | $1.01 | $22K | 815K |
| 2024-02-12 | Taveras Arthur | Chief Scientific Officer | Sell | 787 | $1.01 | $795 | 249K |
| 2024-02-12 | DiBiase Mary | Chief Operating Officer | Sell | 4K | $1.01 | $4K | 307K |
| 2023-11-03 | Ragan Paula | President and CEO | Sell | 40K | $0.90 | $36K | 836K |
| 2023-11-01 | Taveras Arthur | Chief Scientific Officer | Sell | 68K | $0.73 | $49K | 249K |
| 2023-11-01 | Baldry Mark | Chief Commercial Officer | Sell | 10K | $0.73 | $7K | 25K |
| 2023-11-01 | DiBiase Mary | Chief Operating Officer | Sell | 68K | $0.73 | $49K | 311K |
| 2023-11-01 | Mostafa Adam S. | Chief Financial Officer | Sell | 231K | $0.73 | $168K | 80K |
| 2023-11-01 | Ragan Paula | President and CEO | Sell | 200K | $0.73 | $146K | 876K |
| 2023-10-31 | DiBiase Mary | Chief Operating Officer | Grant | 231K | $0.00 | $0 | 379K |
| 2023-10-31 | Ragan Paula | President and CEO | Grant | 532K | $0.00 | $0 | 1.1M |
| 2023-10-31 | Taveras Arthur | Chief Scientific Officer | Grant | 231K | $0.00 | $0 | 317K |
| 2023-10-31 | Baldry Mark | Chief Commercial Officer | Grant | 35K | $0.00 | $0 | 35K |
| 2023-10-31 | Mostafa Adam S. | Chief Financial Officer | Grant | 231K | $0.00 | $0 | 311K |
| 2023-10-16 | Woods Keith | Director | Grant | 90K | $0.00 | $0 | 90K |
| 2023-09-08 | DiBiase Mary | Chief Operating Officer | Sell | 3K | $1.25 | $3K | 148K |
| 2023-08-18 | WYZGA MICHAEL S | Director | Buy | 25K | $1.20 | $30K | 77K |
| 2023-08-10 | Stewart Murray | Interim Chief Medical Officer | Sell | 130K | $1.06 | $138K | 147K |
| 2023-08-09 | Stewart Murray | Interim Chief Medical Officer | Grant | 270K | $0.00 | $0 | 277K |
| 2023-06-30 | Mostafa Adam S. | Chief Financial Officer | Sell | 3K | $1.89 | $5K | 80K |
| 2023-06-30 | DiBiase Mary | Chief Operating Officer | Sell | 464 | $1.89 | $877 | 151K |
| 2023-06-23 | Ragan Paula | President and CEO | Sell | 7K | $1.92 | $13K | 544K |
| 2023-06-23 | Mostafa Adam S. | Chief Financial Officer | Sell | 5K | $1.93 | $10K | 83K |
| 2023-06-23 | DiBiase Mary | Chief Operating Officer | Sell | 857 | $1.93 | $2K | 151K |
| 2023-06-15 | Ragan Paula | President and CEO | Sell | 7K | $2.23 | $15K | 551K |
| 2023-06-15 | Mostafa Adam S. | Chief Financial Officer | Sell | 5K | $2.22 | $12K | 88K |
| 2023-06-15 | DiBiase Mary | Chief Operating Officer | Sell | 857 | $2.23 | $2K | 152K |
| 2023-06-13 | Lawton Alison Frances | Director | Grant | 45K | $0.00 | $0 | 52K |
| 2023-06-13 | de Craecker Francoise | Director | Grant | 45K | $0.00 | $0 | 52K |
| 2023-06-13 | WYZGA MICHAEL S | Director | Grant | 45K | $0.00 | $0 | 52K |
| 2023-06-13 | MCGIRR DAVID W J | Director | Grant | 45K | $0.00 | $0 | 52K |
| 2023-06-13 | Bridger Gary | Director | Grant | 45K | $0.00 | $0 | 52K |
| 2023-06-13 | Aliski William | Director | Grant | 45K | $0.00 | $0 | 52K |
| 2023-05-31 | Ragan Paula | President and CEO | Sell | 6K | $1.95 | $12K | 557K |
| 2023-03-10 | Ragan Paula | President and CEO | Sell | 50K | $0.84 | $42K | 564K |
| 2023-03-10 | Taveras Arthur | Chief Scientific Officer | Sell | 17K | $0.84 | $14K | 86K |
| 2023-03-10 | Mostafa Adam S. | Chief Financial Officer | Sell | 53K | $0.84 | $44K | 94K |
| 2023-03-10 | DiBiase Mary | Chief Operating Officer | Sell | 18K | $0.84 | $15K | 153K |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.
Large holders (13D and 13G)
One row per reporting person with its latest filing, newest first, 50 of 65 shown. JSON44 holders report 5% or more of XFOR in their latest filing, 12 on Schedule 13D (active intent). The largest reported stake is Morgan Stanley at 10.2% of the class (8,884,338 shares), filed 2026-03-06 for an event on 2026-02-28.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-10-07 | 13G/Ano. 2 | Abigail P. Johnsonindividual | 4.6M | 4.6% | 2026-09-30 |
| 2026-10-07 | 13G/Ano. 2 | FMR LLCparent holding company | 4.6M | 4.6% | 2026-09-30 |
| 2026-09-21 | 13G | Venrock Healthcare Capital Partners III, L.P.partnership | 5.6M | 5.6% | 2026-09-14 |
| 2026-09-21 | 13G | VHCP Co-Investment Holdings III, LLCother entity | 5.6M | 5.6% | 2026-09-14 |
| 2026-09-21 | 13G | Venrock Healthcare Capital Partners EG, L.P.partnership | 5.6M | 5.6% | 2026-09-14 |
| 2026-09-21 | 13G | VHCP Management III, LLCother entity | 5.6M | 5.6% | 2026-09-14 |
| 2026-09-21 | 13G | VHCP Management EG, LLCother entity | 5.6M | 5.6% | 2026-09-14 |
| 2026-09-21 | 13G | Nimish Shahindividual | 5.6M | 5.6% | 2026-09-14 |
| 2026-09-21 | 13G | Bong Y. Kohindividual | 5.6M | 5.6% | 2026-09-14 |
| 2026-08-14 | 13G/Ano. 2 | Perceptive Advisors LLCinvestment adviser | 8.1M | 8.1% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 2 | Joseph Edelmanindividual | 8.1M | 8.1% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 2 | Perceptive Life Sciences Master Fund, Ltd.corporation | 8.1M | 8.1% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 1 | David Kroinparent holding company, individual | 8.0M | 8.3% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 1 | Deep Track Capital, LPinvestment adviser, other entity | 8.0M | 8.3% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 1 | Deep Track Biotechnology Master Fund, Ltd.corporation | 6.9M | 7.2% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 1 | Deep Track Special Opportunities Fund, LP.partnership | 1.1M | 1.2% | 2026-06-30 |
| 2026-07-30 | 13G | BlackRock, Inc.parent holding company | 5.5M | 5.9% | 2026-06-30 |
| 2026-03-06 | 13G/Ano. 1 | Morgan Stanleyparent holding company, corporation | 8.9M | 10.2% | 2026-02-28 |
| 2026-03-06 | 13G/Ano. 1 | Morgan Stanley Investment Management Inc.investment adviser, corporation | 8.9M | 10.2% | 2026-02-28 |
| 2026-03-06 | 13G/Ano. 1 | Inception Trustinvestment adviser, corporation | 4.5M | 5.2% | 2026-02-28 |
| 2026-02-17 | 13G/Ano. 1 | Ortav Yehudaiindividual | 5.2M | 5.8% | 2025-12-31 |
| 2026-02-17 | 13G/Ano. 1 | Trails Edge Capital Partners, LPinvestment adviser, partnership | 5.2M | 5.8% | 2025-12-31 |
| 2026-02-17 | 13G/Ano. 1 | Trails Edge Biotechnology Master Fund, LPpartnership | 5.2M | 5.8% | 2025-12-31 |
| 2026-02-17 | 13G/Ano. 1 | BCLS II Equity Opportunities, LPpartnership | 7.0M | 7.4% | 2025-12-31 |
| 2026-02-17 | 13G/Ano. 1 | BCLS II Investco, LPpartnership | 759K | 0.8% | 2025-12-31 |
| 2026-02-17 | 13G/Ano. 1 | BCLS I Investco, LPpartnership | 90K | 0.1% | 2025-12-31 |
| 2026-02-17 | 13G/Ano. 1 | Bain Capital Life Sciences Fund II, L.P.partnership | 64K | 0.1% | 2025-12-31 |
| 2026-02-17 | 13G/Ano. 1 | BCIP Life Sciences Associates, LPpartnership | 8K | 0.0% | 2025-12-31 |
| 2026-02-17 | 13G/Ano. 1 | Bain Capital Life Sciences Fund, L.P.partnership | 0 | 0.0% | 2025-12-31 |
| 2026-02-17 | 13G/Ano. 1 | BVF INC/ILcorporation | 3.4M | 3.9% | 2025-12-31 |
| 2026-02-17 | 13G/Ano. 1 | LAMPERT MARK Nindividual | 3.4M | 3.9% | 2025-12-31 |
| 2026-02-17 | 13G/Ano. 1 | BVF PARTNERS L P/ILinvestment adviser, partnership | 3.4M | 3.9% | 2025-12-31 |
| 2026-02-17 | 13G/Ano. 1 | BVF GP HOLDINGS LLCother entity | 3.2M | 3.6% | 2025-12-31 |
| 2026-02-17 | 13G/Ano. 1 | BIOTECHNOLOGY VALUE FUND L Ppartnership | 1.8M | 2.1% | 2025-12-31 |
| 2026-02-17 | 13G/Ano. 1 | BVF I GP LLCother entity | 1.8M | 2.1% | 2025-12-31 |
| 2026-02-17 | 13G/Ano. 1 | BVF II GP LLCother entity | 1.3M | 1.5% | 2025-12-31 |
| 2026-02-17 | 13G/Ano. 1 | BIOTECHNOLOGY VALUE FUND II LPpartnership | 1.3M | 1.5% | 2025-12-31 |
| 2026-02-17 | 13G/Ano. 1 | Biotechnology Value Trading Fund OS LPpartnership | 195K | 0.2% | 2025-12-31 |
| 2026-02-17 | 13G/Ano. 1 | BVF Partners OS Ltd.corporation | 195K | 0.2% | 2025-12-31 |
| 2026-02-17 | 13G | Xiaoying Tianindividual | 6.4M | 7.4% | 2025-10-24 |
| 2026-02-17 | 13G | Saturn V Capital Management LPinvestment adviser | 6.4M | 7.4% | 2025-10-24 |
| 2026-02-13 | 13G/Ano. 1 | Nantahala Capital Management, LLCinvestment adviser | 2.4M | 2.8% | 2025-12-31 |
| 2026-02-13 | 13G/Ano. 1 | Wilmot B. Harkeyparent holding company | 2.4M | 2.8% | 2025-12-31 |
| 2026-02-13 | 13G/Ano. 1 | Daniel Mackparent holding company | 2.4M | 2.8% | 2025-12-31 |
| 2026-01-15 | 13G/Ano. 1 | Empery Asset Management, LPinvestment adviser, partnership | 9.0M | 10.0% | 2025-12-31 |
| 2026-01-15 | 13G/Ano. 1 | Ryan M. Laneparent holding company, individual | 9.0M | 10.0% | 2025-12-31 |
| 2025-10-29 | 13D/Ano. 4 | Growth Equity Opportunities 18 VGE, LLCother entity | 5.1M | 6.2% | 2025-10-27 |
| 2025-10-29 | 13D/Ano. 4 | NEA 18 Venture Growth Equity, L.P.partnership | 5.1M | 6.2% | 2025-10-27 |
| 2025-10-29 | 13D/Ano. 4 | NEA Partners 18 VGE, L.P.partnership | 5.1M | 6.2% | 2025-10-27 |
| 2025-10-29 | 13D/Ano. 4 | NEA 18 VGE GP, LLCother entity | 5.1M | 6.2% | 2025-10-27 |
13F holders
Tracked managers holding XFOR at their latest 13F. JSON3 of the 30 tracked managers held XFOR at their latest 13F, $367K in total at quarter-end prices. Point72 Asset Management is the largest at $192K (0.0% of its portfolio) as of 2026-06-30. Over the prior quarter 3 added shares and 0 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| Point72 Asset Management | 2026-06-30 | 41K | $192K | 0.00% | new |
| Two Sigma Investments | 2026-06-30 | 19K | $91K | 0.00% | +6K |
| Renaissance Technologies | 2026-06-30 | 18K | $85K | 0.00% | new |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
What this page is
X4 Pharmaceuticals in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.
This page follows X4 Pharmaceuticals (XFOR), SEC CIK 1501697, listed on Nasdaq, classified by the SEC as biological products, (no diagnostic substances). The cross-market tables live on the short interest and insider transactions hubs.
Source and updates
- Short interest
- FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-10-15.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-11-02.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-10-05.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-10-07.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Earnings dates
- SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2025-11-05.JSON and CSV
- Insider trades
- SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-10-16.JSON and CSV
- Company record
- EDGAR filing index for CIK 1501697Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 10 requests a minute without a key, 30 with a free key from a free account.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as biological products, (no diagnostic substances)
Other company pages
- STESTERIS
- STLDSteel Dynamics
- STRCStrategy
- STRLSterling Infrastructure
- STTState Street
- STXSeagate Technology Holdings
- STZConstellation Brands
- SUISun Communities
- SUNBSunbelt Rentals Holdings
- SWSmurfit Westrock
- SWKStanley Black & Decker
- SWKSSkyworks Solutions
- SXTCChina SXT Pharmaceuticals
- SYFSynchrony Financial
- SYKStryker
- SYNASynaptics
Datasets
Frequently Asked Questions
How much of XFOR is sold short?
7,490,770 shares were held short at the 2026-10-15 settlement, 12.5 days of average volume. FINRA publishes the next count about eight business days after the 15th and the last business day of the month.
What is XFOR's daily short volume?
On 2026-11-02, 98,299 of the 209,503 XFOR shares reported to FINRA were sold short, 46.9% of the day's reported volume. Short volume is a flow for one day, not a position.
Does XFOR have fails to deliver?
The SEC's latest file shows 250 XFOR shares failed to deliver at settlement 2026-10-05. Fails are reported per settlement date and published twice a month with a lag.
Are XFOR insiders buying or selling?
Over the last 90 days XFOR insiders reported 1 open-market buy ($12K) against 3 sells ($354K), so the dollar flow leans toward selling. Latest filing: Craig Adam R (Executive Chairman) on 2026-10-16.
Who owns 5% or more of XFOR?
44 holders report 5% or more of XFOR in their latest filing, 12 on Schedule 13D (active intent). The largest reported stake is Morgan Stanley at 10.2% of the class (8,884,338 shares), filed 2026-03-06 for an event on 2026-02-28.
Which tracked 13F managers own XFOR?
3 of the 30 tracked 13F managers held XFOR shares at their latest filing, $367K in all. The largest: Steve Cohen's Point72 Asset Management (41K shares, $192K), Two Sigma Investments (19K shares, $91K), Renaissance Technologies (18K shares, $85K).
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.